

FACT SHEET

MANAGEMENT TEAM

Michael R. Bleavins, Ph.D.
Felix A de la Iglesia, M.D.
Kent J. Johnson, M.D.
David G. Pegg, Ph.D.
James Varani, Ph.D.

SERVICES

- DNA and RNA isolation
- Genotyping by MALDI-TOF, SSP, and RFLP
- Biomarker assay development and validation
- Whole-organ skin culture
- Primary fibroblast and keratinocyte culture
- Cytokine analysis
- Commercial and custom ELISAs
- Advising on the use of genetic testing and biomarkers

EXPERIENCE

- Ninety plus years of applied and basic laboratory research
- Proven success in getting and supporting drugs on the market (*Lyrice, Neurontin, Cognex, Nipent, Lopid*)
- Mechanistic studies for drug efficacy and toxicity
- Integration of biomarkers and genetic testing into drug development programs
- *In vitro* techniques for drug activity and liabilities
- Laboratory strategies and studies to resolve drug development issues
- Comparative approaches to analyze human risk



MICHIGAN TECHNOLOGY
& RESEARCH INSTITUTE

2245 South State Street • Ann Arbor, MI 48104 • 734.222.0013
www.MTRIInstitute.com

“Expediting Time to Decision”

LABORATORY SERVICES OVERVIEW

Michigan Technology and Research Institute, LLC (MITRI) is an integrated pharmaceutical expediting organization with genotyping, cell culture, and biomarker laboratories. MITRI was established to improve decision making and optimize pharmaceutical development strategies that allow identification of high-potential drug molecules. MITRI provides tools, ideas, and laboratory support to help clients establish safety, activity, and efficacy at the earliest possible step in the drug development process.

MITRI’s GLP/GCP compliant laboratories offer development, validation, and conduct of specialized genetic tests and biomarkers to enhance decision making. The Institute provides high-complexity clinical and preclinical testing with proven history of determining the relevance of unexpected or species-specific findings. The cell culture capabilities offer *in vitro* modeling using primary cell types or whole organ skin culture, to assess activity of new chemical entities or established compounds.

MITRI also develops new tests specific to the client’s individual needs or will adapt an existing technique to the client’s specifications. The emphasis is on the application of molecular and cell biology technologies to enhance progress of new molecules or identify novel therapeutic indications for existing drugs. MITRI specializes in providing review and critique of information to clinicians and researchers for protocol development, regulatory filling and due diligence services.

WHY CHOOSE MITRI?

- Help getting to key development milestones more efficiently
- Expertise in specialized testing and risk management
- Experienced consultants for integrating genetic testing into clinical trials
- Expert support for skin physiology, drug responses, and reactions
- Real-world use of translational medicine approaches
- In-house genotyping, cell culture, and biomarker capabilities
- Access to specialized assays and scientists without requiring internal staff
- Options and strategies beyond the obvious for difficult situations
- History of differentiating species-specific responses from human hazard